Souhaitez-vous accéder aux communiqués récents ?

Vänligen ring in på något av följande telefonnummer några minuter före telefonkonferensens start: Från Sverige: +46 (0) 8 505 564 74 Från USA: +1 855 753 22 30 Från Storbritannien: +44...

Details from the Modus Therapeutics press release follow: A planned independent Data Safety Monitoring Board (DSMB) review has been conducted in the multi-centre, randomized Phase II clinical...

Details from the Modus Therapeutics press release follow: The two patents granted by the United States Patent and Trademark Office (USPTO) will provide key intellectual property protection in the...

Detaljer från Umecrine Cognitions pressrelease:    “Vi är mycket uppmuntrade av den farmakodynamiska effektmålet hos GR3027 i våra Fas 1-försök, samt med dess fördelaktiga säkerhets-...

Details from the Umecrine Cognition press release follow:    “We are very encouraged by the pharmacodynamic effect of GR3027 in our Phase 1 trials, along with its favorable safety and...

Tord Lendau brings to Promimic more than 32 years’ of international leadership and board experience from innovative, rapid growth companies. Most recently, he was General Manager at Sandvik MedTech,...

Modus Therapeutics (www.modustx.com) is a clinical-stage drug development company developing new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in rare...

Modus Therapeutics (www.modustx.com) är ett läkemedelsbolag i det kliniska skedet som utvecklar nya farmaceutiska terapier för att återställa begränsat blodflöde och syretransport i ovanliga...

Details from the Promimic press release follow:   Promimic and Danco entered a strategic partnership in March 2016 under which Danco became the preferred process partner for Promimic for...

Details from the Aprea announcement follow:   “The initiation of the Phase II clinical study marks an important milestone for Aprea,” said Christian S. Schade, President and Chief Executive...